SGLT-2 Inhibitors Linked to Lower Epilepsy Risk in Type 2 Diabetes: Study
Written By : Dr. Shravani Dali
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-05-21 03:45 GMT | Update On 2025-05-21 07:33 GMT
Advertisement
A recent population-based study published in Diabetes Care suggests that sodium-glucose cotransporter 2 (SGLT-2) inhibitors, commonly prescribed for type 2 diabetes, may also confer neuroprotective benefits by reducing the risk of epilepsy.
The study found that the use of SGLT-2 inhibitors was associated with a 29% lower incidence of epilepsy compared to dipeptidyl peptidase 4 (DPP-4) inhibitors.
SGLT-2 inhibitors function by inhibiting glucose reabsorption in the kidneys, thereby lowering blood glucose levels. Beyond their glycemic effects, these agents have demonstrated cardiovascular and renal benefits.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.